MOVAPO® for patients with advanced Parkinson's disease

Movapo® is indicated for the acute, intermittent treatment of hypomobility, "OFF episodes ("end-of-dose wearing off and unpredictable "ON/OFF" episodes) in patients with advanced Parkinson's disease.

It is an apomorphine hydrochloride injection (10 mg/mL), supplied as pre-filled pens.

Movapo® is a subcutaneous injection, given as an adjunct to oral medications, and must not be administered intravenously.

Availability: Movapo® is available in packages of 5, 3-mL disposable pens (pre-filled multi-dose pen).

Product	Format	DIN	UPC Code	McKesson code
Movapo Pen 30mg/3mL	(5 x 3mL)	02459132	628791006386	125621

Clinical Use : (not discussed above)

- Initiate treatment with use of a concomitant antiemetic, in a clinical setting where blood pressure and pulse can be closely monitored
- Extra caution in patients >65 years due to potential age-related comorbidities and increased frequency of certain adverse events
- Not recommended in patients <18 years of age

Contraindications:

- Using concomitant drugs of the 5HT3 antagonist class, including antiemetics in this class
- Using concomitant antihypertensive medications or vasodilators
- In patients with severe hepatic or renal impairment

Most Serious Warnings and Precautions:

Sudden Onset of Sleep: Sudden onset of sleep has occurred without warning signs, in patients on Movapo and other dopamine agents, during activities of daily living including driving a motor vehicle. These events are not limited to initiation of therapy and patients should not drive or engage in activities where impaired alertness could put themselves and others at risk of serious injury or death. If drowsiness or sudden onset of sleep occurs, patients should immediately contact their physician.

Other Relevant Warnings and Precautions:

- Increased risk of falling
- Patients should not consume alcohol
- May cause postural/orthostatic hypotension
- Risk of syncope in patients with a history of postural/orthostatic hypotension, syncope, and severe cardiovascular disease
- Patients may experience coronary events or exacerbation of coronary and cerebral ischemia
- Possible QTc prolongation and potential proarrhythmic effects
- Severe nausea and vomiting at recommended doses; use with a concomitant antiemetic
- In patients with a sulfite sensitivity, may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes
- May cause dyskinesia or exacerbate pre-existing dyskinesia
- Rapid dose reduction, withdrawal, or antiparkinsonian therapy changes may cause symptoms resembling neuroleptic malignant syndrome
- May cause somnolence
- Increased susceptibility to retinal atrophy/degeneration in human albinos compared to normally pigmented people cannot be excluded
- Unknown whether non-ergot derived dopamine agonists can cause fibrotic complications
- Not recommended in patients with a major psychotic disorder
- Patients may experience hallucinations, new or worsening mental status, and behavioural changes
- Possible impulse control disorders including compulsive behaviours/intense urges
- May cause prolonged painful erections
- Monitor for melanomas
- Risk of injection site reactions
- Use during pregnancy only if the potential benefit justifies the potential risk to the fetus
- Breast-feeding is not recommended
- Mild and moderate hepatic and renal impairment

For more information:

Please consult the product monograph at http://www.paladin-labs.com/our_products/Movapo_en.pdf for important information relating to adverse reactions, drug interactions, and dosing information that have not been discussed in this piece. The product monograph is also available by calling 1-888-867-7426.

paladin
an endo international company

PAAB

MOVAPO®
apomorphine hydrochloride injection